Adjuvance Technologies
PrivateLast Round
Series A
May 27, 2020
Total Funding Raised
$27.86M
Company Overview
Adjuvance Technologies is a biopharmaceutical company that develops and manufactures proprietary saponin-based vaccine adjuvants to improve immune responses.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials
Business Model
B2B
Customer Profile
Services & Consulting, Data as a Service
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Adjuvance Technologies Comparables
Compare Adjuvance Technologies with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Q-Vant Biosciences | 85% | |
| ImmunAdd Inc. | 84% | |
| TollereBio | 82% |
For institutional investors. Book with your work email.
Adjuvance Technologies Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series A | May 27, 2020 | ||||
| Grant | May 19, 2020 | ||||
| Grant | Sep 1, 2017 | ||||
| Seed | Nov 14, 2016 | ||||
| Grant | Jun 6, 2014 |
For institutional investors. Book with your work email.
Adjuvance Technologies Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| National Institute of Allergy and Infectious Diseases | Grant |
| NIH RADx | Grant |
| Morningside Ventures | Seed, Series A |
| Nebraska Department of Economic Development | Seed |
For institutional investors. Book with your work email.
Market signals
Structured signals derived from secondary market and firmographic data.
- May 27, 2020
$20M round led by Morningside Ventures.
- May 19, 2020
$1.47M grant from National Institute of Allergy and Infectious Diseases
For institutional investors. Book with your work email.
Adjuvance Technologies Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Adjuvance Technologies's valuation, stock price, and market status.
Is Adjuvance Technologies a public or private company?
Adjuvance Technologies is a private company.
What is the current stock price of Adjuvance Technologies?
Adjuvance Technologies is a private company, so its shares have no public market price. Caplight tracks Adjuvance Technologies's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Adjuvance Technologies worth (valuation)?
Valuation information for Adjuvance Technologies is not publicly available.
Can I buy Adjuvance Technologies stock?
Adjuvance Technologies shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Adjuvance Technologies's last funding round?
Adjuvance Technologies's most recent funding round was Series A on May 27, 2020.
Who are the main investors in Adjuvance Technologies?
Key investors in Adjuvance Technologies include Morningside Ventures.
Will Adjuvance Technologies IPO soon?
No public IPO plans have been announced for Adjuvance Technologies.
How can I track Adjuvance Technologies secondary market activity?
Caplight tracks bids, offers, and trades in Adjuvance Technologies's shares on secondary markets.